MedTrace Logo

BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma

NCT03794167 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2019-01-07

No results posted yet for this study

Summary

The investigators developed a protocol comparing busulfan/cyclophosphamide/etoposide (BuCE) and busulfan/melphalan/etoposide (BuME) regimen as a conditioning for high-dose therapy (HDT) in the patients with high risk or relapsed Non-Hodgkin's Lymphoma (NHL).

Conditions

Interventions

DRUG

Busulfan

busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6

DRUG

Cyclophosphamide

cyclophosphamide 50mg/kg/day i.v. on days -3 and -2

DRUG

Etoposide

etoposide 400mg/m2 day i.v. on days -5 and -4

DRUG

Melphalan

melphalan 50mg/m2/day i.v. on days -3 and -2

Sponsors & Collaborators

  • Soonchunhyang University Hospital

    lead OTHER

Principal Investigators

  • Jong-Ho Won, Professor · Soonchunhyang University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-01
Primary Completion
2017-05-30
Completion
2018-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03794167 on ClinicalTrials.gov